Erzincan Binali Yıldırım ÜniversitesiErzincan Binali Yıldırım ÜniversitesiAçık Erişim Arşivi · RDL Open

Inhibitory Effect of Methotrexate (MTX) Used in Human Cancer Treatment on Paraoxonase-1 (PON1)

ArticleAçık Erişim

Özet

Background and Objective: Paraoxonase-1 (PON1) is a lactonase that plays a role in the destruction of carcinogenic free radicals and in reducing oxidative stress. In this article, it was aimed to investigate the inhibitory effect of methotrexate (MTX) on PON1. Materials and Methods: In this study, the inhibition between methotrexate used in cancer chemotherapy and PON1 was studied. Results: Methotrexate showed very strong inhibitory properties for human serum PON1, with an IC(50)value of 38.50 mu M and a mean K-i value of 42.36 mu M. Hence methotrexate showed competitive inhibition. Conclusion: The widespread use of methotrexate, a dihydrofolate reductase (DHFR) inhibitor, in the treatment of human cancers can be very harmful.

Anahtar Kelimeler

PON1methotrexateinhibitionanticancer drugoxidative stressLDLatherosclerosisHUMAN SERUM PARAOXONASE-1HYDROCHLORIDEHPON1Pharmacology & Pharmacy
RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/16785Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.3923/ijp.2022.942.946Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorSoyut, Hakan
dc.contributor.authorUlutas, Yakup
dc.contributor.authorKoksal, Ekrem
dc.date.accessioned2026-10-18T20:38:54.161512083Z
dc.date.available2026-10-18T20:38:54.161512083Z
dc.date.issued2022
dc.description.abstractBackground and Objective: Paraoxonase-1 (PON1) is a lactonase that plays a role in the destruction of carcinogenic free radicals and in reducing oxidative stress. In this article, it was aimed to investigate the inhibitory effect of methotrexate (MTX) on PON1. Materials and Methods: In this study, the inhibition between methotrexate used in cancer chemotherapy and PON1 was studied. Results: Methotrexate showed very strong inhibitory properties for human serum PON1, with an IC(50)value of 38.50 mu M and a mean K-i value of 42.36 mu M. Hence methotrexate showed competitive inhibition. Conclusion: The widespread use of methotrexate, a dihydrofolate reductase (DHFR) inhibitor, in the treatment of human cancers can be very harmful.
dc.identifier.doi10.3923/ijp.2022.942.946
dc.identifier.eissn1812-5700
dc.identifier.endpage946
dc.identifier.issn1811-7775
dc.identifier.issue5
dc.identifier.startpage942
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/16785
dc.identifier.volume18
dc.identifier.wosWOS:000859917600011
dc.language.isoen
dc.publisherASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET
dc.relation.ispartofINTERNATIONAL JOURNAL OF PHARMACOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPON1
dc.subjectmethotrexate
dc.subjectinhibition
dc.subjectanticancer drug
dc.subjectoxidative stress
dc.subjectLDL
dc.subjectatherosclerosis
dc.subjectHUMAN SERUM PARAOXONASE-1
dc.subjectHYDROCHLORIDE
dc.subjectHPON1
dc.subjectPharmacology & Pharmacy
dc.titleInhibitory Effect of Methotrexate (MTX) Used in Human Cancer Treatment on Paraoxonase-1 (PON1)
dc.typeArticle
dspace.entity.typePublication
rdl.citation.wos2
rdl.source.indexWOS
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)